London stock exchange
Stocks and Finance

Elan

Elan 27/04/2012

03:56 : Elan pins its hopes on Tysabri as 17pc revenue rise beats forecasts - IRISH drug company Elan reckons that it will have about 130,000 patients using its multiple sclerosis treatment Tysabri within the next five years, as revenues from the product continue to surge.
Source : independent-ie

Elan 26/04/2012

09:26 : Elan 'on track' for $1.2bn revenue - Irish biotech firm Elan grew its revenue and said it was on track to meet its guidance for the year, as it put in a “solid” performance ion the first quarter.
Source : irishtimes-com

Elan 14/04/2012

04:55 : Novartis unsure on MS drug link to case - SWISS drug maker Novartis said it's still not sure whether its new multiple sclerosis (MS) treatment contributed to a patient on the drug contracting a potentially deadly brain infection. The patient has been taking Gilenya, a drug approved ...
Source : independent-ie

Elan 13/04/2012

10:56 : UPDATE: Novartis MS Pill Gilenya Patient Gets Rare Brain Disease - -- Development comes as Gilenya's safety is under scrutiny by European regulators -- Patient had been previously treated with Elan and Biogen's MS drug Tysabri -- Analysts say case should be taken seriously as adds to Gilenya safety concerns ...
09:48 : Novartis: MS Pill Gilenya Patient Develops Rare Brain Disease - ZURICH -(Dow Jones)- Novartis AG (NVS) Friday said a patient treated with its multiple-sclerosis pill Gilenya has been diagnosed with a rare and often fatal brain disease. The Swiss drug maker said the patient had been previously treated ...

Elan 14/03/2012

05:35 : Elan sells Alkermes shares for $381m - IRISH drug company Elan has confirmed the completion of a sale of shares in New York-listed Alkermes for $381m (€290m). Elan held a 25pc stake in Alkermes after it sold its drug technology unit to the company last year for close ...
Source : independent-ie

Elan 02/03/2012

12:12 : Elan's Martin delays departure until drug-trial data is revealed - The chief executive of Irish drug company Elan, Kelly Martin, has postponed his departure from the group until potentially "transformational" data from an Alzheimer's drug trial is made public later this year.
Source : independent-ie

Elan 20/01/2012

22:06 : Elan may change drug information - Irish biotech group Elan and its US partner Biogen Idec have won US clearance to modify the label of their multiple-sclerosis shot Tysabri with new safety information that may double the treatment's worldwide sales.
Source : irishtimes-com

Elan 27/11/2011

09:44 : Elan to create research centre with Cambridge University - DUBLIN (Reuters) - Elan Corp Plc has signed an agreement with Cambridge University to create a research centre focussed on therapies for Alzheimer's and Parkinson's, the Dublin-headquartered biotech group said on Sunday.
Source : reuters-com

Elan 29/10/2011

09:13 : Elan chief downplays threat to blockbuster Tysabri - The boss of Irish drug firm Elan, Kelly Martin, says he doesn't believe sales of the company's blockbuster multiple sclerosis treatment Tysabri will be adversely impacted by a likely launch of a new rival product from its US partner.
Source : independent-ie

Elan 12/08/2011

04:40 : Complaint on Elan 'can't be amended' - A US judge has told lawyers representing two attempted class-action suits against Irish drug firm Elan they cannot amend a complaint dismissed by the court in June. The plaintiffs in the case had claimed against Elan, alleging the ...
Source : independent-ie

Elan 28/07/2011

04:30 : MS drug sales help Elan cut losses - Irish pharmaceutical group Elan sharply narrowed its second-quarter net loss to $47.1m (€32.8m) from $218m a year earlier as sales of its multiple sclerosis treatment Tysabri increased and the impact of a one-off $200m-plus legal settlement ...
Source : independent-ie

Elan 27/07/2011

07:32 : Elan cuts net loss to $47 million - Irish biotech company Elan re-affirmed its full-year guidance this morning after reporting a 24 per cent jump in revenue for the second quarter of the year.
Source : irishtimes-com

Elan 23/06/2011

10:22 : Elan boosted as EC says it can include warning note with Tysabri - IRISH drug company Elan has received the go-ahead from the European Commission to include information on its Tysabri multiple-sclerosis drug, warning patients and doctors that having specific virus antibodies is a risk factor in developing ...
Source : independent-ie

Elan 27/05/2011

08:20 : Elan open to further buys but focus still on Tysabri revenue - ELAN chief executive Kelly Martin has said the firm will consider acquisitions of companies with existing revenue streams if suitable candidates are identified.
Source : independent-ie
actualidad Elan -

Elan by date

Copyright © 2009 Finaperf.com - Bourse - Börse - Day trading - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts